NCT02564614已完成1 期
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 7
- 主要终点
- Change From Baseline to Week 6 in HIF1A mRNA Level in Tumor Tissue
研究概览
简要总结
This open-label study will demonstrate proof-of-mechanism of HIF1A inhibition by a decrease of HIF1A mRNA after intravenous (IV) infusion of RO7070179 in participants with hepatocellular carcinoma (HCC) who have failed at least one line of systemic therapy. This will be a single arm study and all participants will receive RO7070179, 13 milligram per kilogram per week (mg/kg/week), 2-hour IV infusion on Days 1 and 4 during Week 1 of Cycle 1, followed by once weekly in 6 week cycle. Treatment with RO7070179 will be continued until disease progression or unacceptable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female of >=18 years of age with the Eastern Cooperative Oncology Group (ECOG) performance status 0-1, Child-Pugh score of 5-7, and Life expectancy of 3 months or greater.
- •Confirmed to have HCC as described by the American Association for the Study of Liver Disease (AASLD).
- •Participants who have failed at least one line of systemic therapy for advanced stage HCC or participants who are ineligible or unable to tolerate the standard of care treatment.
- •Have measurable or evaluable disease.
- •Participants with normal major organ functions as defined by hemoglobin (HgB) >= 8.5 gram/decilitre (dL), absolute neutrophil count (ANC) >= 1000/microliter (mcL), platelet >= 60,000/micL, aspartate aminotransferase/alanine transaminase (AST/ALT) <= 3 x Upper Limit of Normal (ULN), total Bilirubin <= 2 x ULN, creatinine <= 2 x ULN.
- •Willingness to undergo two tumor biopsies: before and after administration of RO7070179.
排除标准
- •Concurrent serious medical illness that could potentially interfere with protocol compliance (such medical illness will not include hepatitis or cirrhosis, as the degree of liver impairment caused by these diseases are covered by other exclusion criteria).
- •Active hepatitis B or C, but participants on stable medications for hepatitis B or C.
- •Bleeding esophageal or gastric varices within 2 months before enrollment.
- •Participants who need to take therapeutic anti-coagulation or anti-platelet therapy.
- •Presence of ascites that preclude biopsy of liver lesions.
- •History of unstable angina or myocardial infarction within 12 months prior to Day 1 or ischemic heart disease.
- •Known HIV positive and positive screening pregnancy test or is breast-feeding.
- •Female or male of reproductive capacity unwilling to use methods of contraception to prevent pregnancy during this study. Participants unwilling to use methods of contraception to prevent pregnancy for 6 months after the last dose of RO7070179 due to the potential for prolonged half-life of RO7070179 in the liver.
- •Known, clinically suspected, or history of CNS tumor involvement.
- •Prior chemotherapy, immunotherapy, investigational therapeutic agent, or other therapy used to treat HCC within 4 weeks before the first scheduled administration of RO
- •Participants who have not recovered from any reversible side effects (except alopecia) to Grade 0 or 1 toxicity attributed to the administration of an investigational therapeutic agent, chemotherapy, immunotherapy, radiotherapy, or other agents previously used to treat the cancer.
- •Any condition that, in the opinion of the investigator or the Sponsor, makes the patients unsuitable for the study.
- •Inability to comply with the study protocol.
研究组 & 干预措施
RO7070179
Experimental
Participants will receive RO7070179, 13 mg/kg/week, 2-hour IV infusion every week in a 6-week cycle, after two loading doses in Week 1 of Cycle 1 on Day 1 and Day 4. If a dose-limiting toxicity (DLT) occurs in more than 33% of participants at any time, the dose will be reduced to 10 mg/kg/week. The dose will be further reduced to 6 mg/kg/week if more than 33% of treated participants have a DLT.
干预措施: RO7070179 (Drug)
结局指标
主要结局
Change From Baseline to Week 6 in HIF1A mRNA Level in Tumor Tissue
时间窗: Pre-dose (baseline) and Week 6
次要结局
- Change From Baseline to Week 6 in hypoxia-inducible factor 1a (HIF1A) Tumor Concentrations(Pre-dose (baseline) and Week 6)
- Change From Baseline to Week 6 in HIF2 Tumor Concentrations(Pre-dose (baseline) and Week 6)
- Change From Baseline to Week 6 in Vascular Endothelial Growth Factor (VEGF) Tumor Concentrations(Pre-dose (baseline) and Week 6)
- Change From Baseline to Week 6 in Erythropoietin (EPO) Tumor Concentrations(Pre-dose (baseline) and Week 6)
- Change From Baseline to Week 6 in Prolyl 4 Hydroxylase Tumor Concentrations(Pre-dose (baseline) and Week 6)
- Percentage of Participants With Complete Response (CR) and Partial Response (PR) According to RECIST and mRECIST(Every 12 weeks upto 24 Months)
- Duration of Response (DOR) According to RECIST and mRECIST(Every 12 weeks upto 24 Months)
- Change From Baseline to Week 6 in CD34/von Willebrand factor (VWF) Tumor Concentrations(Pre-dose (baseline) and Week 6)
- Change in Blood Alpha-fetoprotein (AFP) Concentrations from Baseline(Week 1 and Week 4 for Cycle 1 and at Week 1 for subsequent treatment cycles)
- Time to Progression (TTP) According to Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST)(Every 12 weeks upto 24 Months)
- Progression Free Survival (PFS) According to RECIST and mRECIST(Every 12 weeks upto 24 Months)
- Overall Survival (OS) According to RECIST and mRECIST(Every 12 weeks upto 24 Months)
- Percentage of Participants With Tumor Growth According to RECIST and mRECIST(Every 12 weeks upto 24 Months)
- Maximum Observed Plasma Concentration (Cmax)(pre- and post-dose at Week 1, Week 6)
- Time to Reach Maximum Observed Plasma Concentration (Tmax)(pre- and post-dose at Week 1, Week 6)
- Area under the Concentration-Time Curve From Zero to 168 Hours [AUC (0-168 hours)](pre- and post-dose at Week 1, Week 6)
- Plasma Decay Half-Life (t1/2)(pre- and post-dose at Week 1, Week 6)
研究者
研究点 (7)
Loading locations...
相似试验
撤回
1 期
Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular DegenerationAge Related Macular DegenerationAMDCNVNCT00726466Vitreous -Retina- Macula Consultants of New York
已完成
1 期
The Effect of Hepatic Impairment on Aprocitentan PharmacokineticsHepatic ImpairmentHealthy SubjectsNCT04252495Idorsia Pharmaceuticals Ltd.17
已完成
2 期
A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGNC3 GlomerulonephritisC3 GlomerulopathyImmune Complex Mediated Membranoproliferative GlomerulonephritisMembranoproliferative Glomerulonephritis Types I, II, and IIIDense Deposit DiseaseNCT03124368Alexion Pharmaceuticals, Inc.6
已完成
1 期
PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)TuberculosisNCT02216331Global Alliance for TB Drug Development32
已完成
1 期
Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus ErythematosusSystemic Lupus ErythematosusHIV InfectionsNCT03618056National Institute of Allergy and Infectious Diseases (NIAID)1